Prostate Cancer Trials

ENZAMET Trial

Enzalutamide is a new hormone treatment taken as tablets. Previous trials have proven that enzalutamide improves survival and quality of life in men with prostate cancer that has stopped responding to standard hormone treatments and chemotherapy. This large, international randomised trial will determine if treatment with enzalutamide can improve survival and quality of life in men starting hormone treatment for newly diagnosed prostate cancer that has spread beyond the prostate. The trial is being led from Australia by ANZUP in collaboration with the NHMRC Clinical Trials Centre. It will involve 1,100 men from Australia, New Zealand, Canada, the US, Ireland, and the UK.

This trial is now closed to recruitment. 


ENZARAD Trial

Enzalutamide is a new hormone treatment taken as tablets. Previous trials have proven that enzalutamide improves survival and quality of life in men with prostate cancer that has stopped responding to standard hormone treatments and chemotherapy. This large, international randomised trial will determine if treatment with enzalutamide can improve survival and quality of life in men starting radiation and hormone therapy for prostate cancer that does not seem to have spread beyond the prostate. The trial is being led from Australia by ANZUP in collaboration with the NHMRC Clinical Trials Centre. It is planned to include 800 men from Australia, New Zealand, Canada, the US, Ireland, and the UK.  

Interested in this trial? Print off the ENZARAD Trial details from the Australia New Zealand Clinicial Trials Registry and take it to your GP.

 

Living Well with Prostate Cancer

Prostate cancer is the most common male cancer in developed countries and there are approximately 22,000 Australian men alive today with advanced prostate cancer. Research into the impact of advanced prostate cancer shows that men report higher levels of psychological distress, poorer quality of life, and have an increased risk of suicide compared to men with localised disease. Additionally, many men report they do not receive enough support after their diagnosis. This project is trialling a professionally led and telephone delivered mindfulness-based cognitive therapy (MBCT) group intervention for men with advanced prostate cancer. MBCT is designed to assist men with stress management and improve their psychological wellbeing and in this trial its effectiveness will be compared to an educational program consisting of the best available resources for men with advanced prostate cancer.



Pain-Free TRUS B Trial

A prostate biopsy involves taking small pieces of the prostate through a needle so that it can be looked at with a microscope. A TransRectal UltraSound (TRUS) guided biopsy is the usual way of performing a biopsy and involves inserting a thin needle through the wall of the rectum into the prostate using the guidance of an ultrasound probe. An injection of a local anaesthetic (lignocaine) around the prostate is the standard way of reducing the discomfort of a prostate biopsy.  
 
Methoxyflurane (Penthrox®) is a drug given with a simple inhaler and is widely used by first aid services to reduce pain. This randomised trial will determine if the discomfort of prostate biopsies can be reduced by giving men inhaled methoxyflurane in addition to their standard injections of local anaesthetic. This study will include 420 men and is being conducted by ANZUP Cancer Trials Group in collaboration with the NHMRC Clinical Trials Centre, University of Sydney.

We acknowledge MDI for the provision of Penthrox®. 

Interested in this trial? Print off the Pain-Free TRUS B Trial details from the Australia New Zealand Clinicial Trials Registry and take it to your GP.

© ANZUP 2018. All rights reserved.